REN, D.; CHAUVEAU, G.; VENDOMELE, J.; CABON, E.; PINEIRO, A.; VIGNAL-CLERMONT, C.; SALIBA, H.; RONZITTI, G.; GALY, A.; DALKARA, D.; PULMAN, J.; AIL, D.; FISSON, S.

Adeno-associated viruses (AAVs) have been used in gene therapy, especially for inherited retinal diseases. Despite their effectiveness in gene transduction, immune responses to the AAV capsid and transgene products have been reported, which can compromise both the efficacy and safety of AAV-mediated therapies. The eye is regarded as an immune-privileged organ where immune activity is constitutively suppressed. Here, we highlighted that immunomonitoring in an ocular gene therapy clinical trial and a non-human primate experiment revealed variable immune responses. We further explored factors contributing to this variability, investigating the correlation among immune parameters in a controlled experimental setting. In a syngeneic murine model, which was genetically identical and immunologically compatible, we administered subretinal injections of AAV and analyzed innate, adaptive cellular, and adaptive humoral immune responses. Our results highlight the inter-individual variability of immune parameters, emphasizing the importance of considering inherent variability among individuals while designing personalized therapies.